SCHEMBL30748835

SCHEMBL30748835

Nc1nc(CO)nc(Nc2ccc(Oc3ccccc3)cc2)n1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 10/20 0.57
L3MBTL1 Q9Y468 6/20 0.57
ALDH1A1 P00352 5/20 0.57
POLB P06746 2/20 0.57
MAPK1 P28482 2/20 0.57
USP2 O75604 1/20 0.57
TP53 P04637 1/20 0.57
RAB9A P51151 7/20 0.56
NPC1 O15118 6/20 0.56
HTT P42858 5/20 0.56
KMT2A Q03164 5/20 0.56
JAK2 O60674 4/20 0.53
KDM4E B2RXH2 3/20 0.53
PKM P14618 1/20 0.53
TNF P01375 1/20 0.50
NOD1 Q9Y239 1/20 0.50
MEN1 O00255 4/20 0.48
SMN1; SMN2 Q16637 3/20 0.48
LMNA P02545 2/20 0.48
PIN1 Q13526 2/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30749057 0.90 MAPT (0.55) MAPTL3MBTL1ALDH1A1POLBMAPK1
SCHEMBL12136154 0.86 NPC1 (0.76) MAPTL3MBTL1ALDH1A1POLBMAPK1
SCHEMBL30748820 0.86 NPC1 (0.76) MAPTL3MBTL1ALDH1A1POLBMAPK1
SCHEMBL31691293 0.82 MAOB (0.46) MAPTL3MBTL1ALDH1A1POLBMAPK1
SCHEMBL31691209 0.82 MAPT (0.61) MAPTL3MBTL1ALDH1A1POLBMAPK1
SCHEMBL30748994 0.80 RAB9A (0.55) MAPTL3MBTL1ALDH1A1POLBRAB9A
SCHEMBL30749027 0.78 ALDH1A1 (0.58) MAPTL3MBTL1ALDH1A1POLBMAPK1
SCHEMBL30748817 0.77 SCN9A (0.54) MAPTRAB9ANPC1KMT2AMEN1
SCHEMBL13752171 0.77 PIN1 (0.55) MAPTL3MBTL1ALDH1A1MAPK1TP53
SCHEMBL31691285 0.76 ALDH1A1 (0.57) MAPTL3MBTL1ALDH1A1POLBMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250304571-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF SUZHOU KEEN THERAPEUTICS CO., LTD. (CN) 2025-10-02 US disclosed
EP-4565588-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF Suzhou Keen Therapeutics Co., Ltd. (CN) 2025-06-11 EP disclosed
WO-2023241620-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF SUZHOU KEEN THERAPEUTICS CO., LTD. (CN) 2023-12-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250304571-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF VHL, BRCA1, TERT MAPT 3029/4885L3MBTL1 517/4885ALDH1A1 256/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.